Insulin annual sales

Patent protection for many early biopharmaceuticals, such as recombinant insulin, EPO, hCH and lEN-a, is now nearing or at an end (see also Part VIII, Chapter 3). Most of these are blockbuster products -each commands annual sales well in excess of 1 billion and hence these represent attractive targets for the fledgling biopharmaceutical generics industry [34] (see... 

Erythropoietin has remained the best-selling human medicine for the past 3 years, followed by Lipitor (Atorvastatin), and both of these had over 12 billion in sales [20-22]. The sales of erythropoietin in Japan were over 1 billion. Tumor necrosis factor inhibitors, interferons, and insulins with, respectively, sales of 8.6 billion, 7.3 billion, and 6.5 billion in 2005 were the third, fourth, and fifth bestselling products after EPO and Lipitor (Table 1.5-8) [20-22, 24, 25]. The time taken to reach 1 billion annual sales for monoclonal antibodies has varied and was much faster for follow up and cancer products (Fig. 1.5-1). Rituxan is the leading antibody since 2003 by sales. The growth of Avastin and Erbitux has been much faster as compared to Herceptin and took only two years to reach 1 billion sales. 

The U.S. market for dmgs to control blood glucose totals about 1 x 10 , equally divided between insulin and all other antidiabetic dmgs (33). Insulin sales ate expected to grow by about 10% annually, whereas the antidiabetic dmg market as a whole is expected to shrink by about 3%. The blood glucose monitoring market totals about 7.5 x 10 in the United States and is expected to grow at a rate of 10% annually. 

After the approval of the first product, recombinant insulin, in 1982, progress in the development of new recombinant protein pharmaceuticals was slow ([10], Fig. 17.1). The number of biotechnology-derived drugs and vaccines approved by the US Food and Dmg Administration (FDA) has increased significantly only since 1995. More recently, sales of biologies have skyrocketed, e.g. from 900 million in 1999 to an estimated 3.5 billion in 2001 for monoclonal antibodies [11]. The annual global market for biopharmaceuticals is estimated to have increased from 12 billion US to 30 billion US in 2003 [12]. 500 candidate biopharmaceuticals are undergoing clinical evaluation and over one hundred protein-based therapeutics are in the... 

---